Skip to main content

Table 4 Malignancy rate according to TBSRTC, ACR TI-RADS score and 2015 ATA pattern in 140 indeterminate thyroid nodules

From: ACR TI-RADS and ATA US scores are helpful for the management of thyroid nodules with indeterminate cytology

Classification

 

Final Diagnosis

   

Number of cases

Benign (n = 74)

Malignant (n = 66)

Risk of malignancy (%)

P* value

OR (CI 95%)

TBSRTC

 Bethesda III

44

37

7

15.9%

  

 Bethesda IV

52

31

21

40.4%

  

 Bethesda V

44

6

38

86.4%

< 0.001

 

TBSRTC groups

 III

44

37

7

15.9%

  

 IV/V

96

37

59

61.5%

< 0,001

8.43 (3.37–21.1)

ACR TI-RADS

 TR2

5

4

1

20.0%

  

 TR3

43

33

10

23.3%

  

 TR4a

32

23

9

28.1%

  

 TR4b

9

4

5

55.6%

  

 TR4c

23

8

15

65.2%

  

 TR5

28

2

26

92.9%

< 0.001

 

ACR TI-RADS groups

 TR2/TR3/TR4a

80

60

20

25.0%

  

 TR4b/TR4c/TR5

60

14

46

76.7%

< 0.001

9.86 (4.46–21.8)

2015 ATA patterns

 Very low

5

4

1

20.0%

  

 Low

43

33

10

23.3%

  

 Intermediate

36

27

9

25.0%

  

 High

56

10

46

82.1%

< 0.001

 

2015 ATA groups

 Very low / low / intermediate

84

64

20

23.8%

  

 High

56

10

46

82.1%

< 0.001

14.7 (6.24–34.7)

  1. *Logistic regression models and Wald test; p < 0.05
  2. Abbreviations: ACR TI-RADS American College of Radiology Thyroid Imaging Reporting and Data System, ATA American Thyroid Association, CI confidence interval, OR odd ratios, TBSRTC The Bethesda System for Reporting Thyroid Cytopathology
Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us